Literature DB >> 25240932

Rapid screening and detection of XOD inhibitors from S. tamariscina by ultrafiltration LC-PDA-ESI-MS combined with HPCCC.

Jing Wang1, Shu Liu, Bing Ma, Lina Chen, Fengrui Song, Zhiqiang Liu, Chun-ming Liu.   

Abstract

Xanthine oxidase (XOD) catalyzes the metabolism of hypoxanthine and xanthine to uric acid, the overproduction of which could cause hyperuricemia, a risk factor for gout. Inhibition of XOD is a major treatment for gout, and biflavonoids have been found to act as XOD-inhibitory compounds. In this study, ultrafiltration liquid chromatography with photodiode-array detection coupled to electrospray-ionization tandem mass spectrometry (UF-LC-PDA-ESI-MS) was used to screen and identify XOD inhibitors from S. tamariscina. High-performance counter-current chromatography (HPCCC) was used to separate and isolate the active constituents of these XOD inhibitors. Furthermore, ultrahigh-performance liquid chromatography (UPLC) and triple-quadrupole mass spectrometry (TQ-MS) was used to determine the XOD-inhibitory activity of the obtained XOD inhibitors, and enzyme kinetics was performed with Lineweaver-Burk (LB) plots using xanthine as the substrate. As a result, two compounds in S. tamariscina were screened as XOD inhibitors: 65.31 mg amentoflavone and 0.76 mg robustaflavone were isolated from approximately 2.5 g S. tamariscina by use of HPCCC. The purities of the two compounds obtained were over 98 % and 95 %, respectively, as determined by high-performance liquid chromatography (HPLC). Lineweaver-Burk plot analysis indicated that amentoflavone and robustaflavone were non-competitive inhibitors of XOD, and the IC 50 values of amentoflavone and robustaflavone for XOD inhibition were 16.26 μg mL(-1) (30.22 μmol L(-1)) and 11.98 μg mL(-1) (22.27 μmol L(-1)), respectively. The IC 50 value of allopurinol, used as the standard, was 7.49 μg mL(-1) (46.23 μmol L(-1)). The results reveal that the method for systematic screening, identification, and isolation of bioactive components in S. tamariscina and for detecting their inhibitory activity using ultrafiltration LC-ESI-MS, HPCCC, and UPLC-TQ-MS is feasible and efficient, and could be expected to extend to screening and separation of other enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25240932     DOI: 10.1007/s00216-014-8132-x

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  5 in total

1.  Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia.

Authors:  Bin Han; Chun-Xia Zhu; Wan Shi; Hui-Zhu Huang; Xu-Guang Hu; Xiao-Ming Zhou; Ming Lei; Zhong Li
Journal:  Chin J Integr Med       Date:  2017-01-24       Impact factor: 1.978

2.  Potential Antioxidative Components in Azadirachta indica Revealed by Bio-Affinity Ultrafiltration with SOD and XOD.

Authors:  Min-Xia Fan; Gui-Lin Chen; Ming-Quan Guo
Journal:  Antioxidants (Basel)       Date:  2022-03-29

Review 3.  A Review on the Phytochemistry, Pharmacology, and Pharmacokinetics of Amentoflavone, a Naturally-Occurring Biflavonoid.

Authors:  Sheng Yu; Hui Yan; Li Zhang; Mingqiu Shan; Peidong Chen; Anwei Ding; Sam Fong Yau Li
Journal:  Molecules       Date:  2017-02-16       Impact factor: 4.411

4.  Potential Value of Serum Uric Acid in the Identification of Postoperative Delirium in Geriatric Patients Undergoing Knee Replacement.

Authors:  Fei Wang; Xinhui Tang; Jiahan Wang; Siyv Liu; Xiaoyue Wu; Rui Dong; Xu Lin; Bin Wang; Yanlin Bi
Journal:  Front Aging Neurosci       Date:  2022-07-14       Impact factor: 5.702

5.  Integration of in vitro and in silico perspectives to explain chemical characterization, biological potential and anticancer effects of Hypericum salsugineum: A pharmacologically active source for functional drug formulations.

Authors:  Onur Bender; Eulogio J Llorent-Martínez; Gokhan Zengin; Adriano Mollica; Ramazan Ceylan; Lucia Molina-García; Maria Luisa Fernández-de Córdova; Arzu Atalay
Journal:  PLoS One       Date:  2018-06-04       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.